Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Weide, Benjamin ^a   Faller, Christine ^a   Elsässer, Margrit ^a   Büttner, Petra ^b   Pflugfelder, Annette ^a   Leiter, Ulrike ^a   Eigentler, Thomas Kurt ^a   Bauer, Jürgen ^a   Meier, Friedegund ^a   Garbe, Claus ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENDER; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; ULCER;

ADULT; AGED; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; RECURRENCE; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84879388975     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066953     Document Type: Article

References (43)

1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, et al. (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28: 2452-2459.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206.
3. Leiter U, Buettner PG, Eigentler TK, Forschner A, Meier F, et al. (2010) Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? Melanoma Res 20: 240-246.
4. Elsaesser O, Leiter U, Buettner PG, Eigentler TK, Meier F, et al. (2012) Prognosis of sentinel node staged patients with primary cutaneous melanoma. PLoS ONE 7: e29791.
5. Callender GG, Gershenwald JE, Egger ME, Scoggins CR, Martin RC, et al. (2012) A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. J Am Coll Surg 214: 608-617.
6. Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, et al. (2010) Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol 17: 2006-2014.
7. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648.
8. Herman K, Wysocki WM, Skotnicki P, Tabor J, Luczynska E, et al. (2009) Stage III thick (>4.0 mm) lower extremity melanoma: is timing of lymph node involvement a prognostic factor? World J Surg 33: 469-474.
9. Konstadoulakis MM, Messaris E, Zografos G, Ricaniadis N, Androulakis G, et al. (2002) Common prognostic factors for stage III melanoma patients and for stage I and II melanoma patients with recurrence to their regional lymph nodes. Melanoma Res 12: 357-364.
10. Roses DF, Karp NS, Oratz R, Dubin N, Harris MN, et al. (1991) Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet 172: 262-268.
11. Kretschmer L, Preusser KP, Marsch WC, Neumann C, (2000) Prognostic factors of overall survival in patients with delayed lymph node dissection for cutaneous malignant melanoma. Melanoma Res 10: 483-489.
12. Nowecki ZI, Rutkowski P, Michej W, (2008) The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol 15: 2223-2234.
13. Buzzell RA, Zitelli JA, (1996) Favorable prognostic factors in recurrent and metastatic melanoma. J Am Acad Dermatol 34: 798-803.
14. Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, et al. (2005) Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 15: 77-82.
15. Schlagenhauff B, Stroebel W, Ellwanger U, Meier F, Zimmermann C, et al. (1997) Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer 80: 60-65.
16. Chang P, Knapper WH, (1982) Metastatic melanoma of unknown primary. Cancer 49: 1106-1111.
17. Saleh FH, Crotty KA, Hersey P, Menzies SW, (2001) Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int J Cancer 94: 551-557.
18. Giuliano AE, Cochran AJ, Morton DL, (1982) Melanoma from unknown primary site and amelanotic melanoma. Semin Oncol 9: 442-447.
19. Lee CC, Faries MB, Wanek LA, Morton DL, (2008) Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 26: 535-541.
20. Cormier JN, Xing Y, Feng L, Huang X, Davidson L, et al. (2006) Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 106: 2012-2020.
21. Prens SP, van der Ploeg AP, van Akkooi AC, van Montfort CA, van Geel AN, et al. (2011) Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site. Ann Surg Oncol.
22. Reintgen DS, McCarty KS, Woodard B, Cox E, Seigler HF, (1983) Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet 156: 335-340.
23. Anbari KK, Schuchter LM, Bucky LP, Mick R, Synnestvedt M, et al. (1997) Melanoma of unknown primary site: presentation, treatment, and prognosis-a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer 79: 1816-1821.
24. Sondak VK, Tuthill R, Moon J, Thompson JA, Lao CD, et al. (2010) Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008. ASCO Meeting Abstracts 28: 8517.
25. Weide B, Elsasser M, Buttner P, Pflugfelder A, Leiter U, et al. (2012) Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 107: 422-428.
26. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL, (2004) Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139: 961-966.
27. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, et al. (1999) Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol 38: 549-557.
28. Francken AB, Accortt NA, Shaw HM, Wiener M, Soong SJ, et al. (2008) Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 15: 1476-1484.
29. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA, (1981) A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 193: 377-388.
30. Messeguer F, Agusti-Mejias A, Traves V, Requena C, Alegre V, et al. (2012) Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma. J Eur Acad Dermatol Venereol (published online first).
31. Carlson JA, (2003) Tumor doubling time of cutaneous melanoma and its metastasis. Am J Dermatopathol 25: 291-9.
32. Mihm MC Jr, Clemente CG, Cascinelli N, (1996) Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74: 43-7.
33. van Akkooi AC, Bouwhuis MG, van Geel AN, Hoedemaker R, Verhoef C, et al. (2007) Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol 33: 102-108.
34. Rutkowski P, Nowecki ZI, Dziewirski W, Zdzienicki M, Pienkowski A, et al. (2010) Melanoma without a detectable primary site with metastases to lymph nodes. Dermatol Surg 36: 868-876.
35. Norman J, Cruse CW, Wells KE, Saba HI, Reintgen DS, (1992) Metastatic melanoma with an unknown primary. Ann Plast Surg 28: 81-84.
36. Menzies SW, McCarthy WH, (1997) Complete regression of primary cutaneous malignant melanoma. Arch Surg 132: 553-556.
37. Ribero S, Quaglino P, Osella-Abate S, Sanlorenzo M, Senetta R, et al. (2012) Relevance of multiple basin drainage and primary histologic regression in prognosis of trunk melanoma patients with negative sentinel lymph nodes. J Eur Acad Dermatol Venereol 10-3083.
38. Shaw HM, McCarthy SW, McCarthy WH, Thompson JF, Milton GW, (1989) Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases. Histopathology 15: 257-265.
39. Wong JH, Cagle LA, Morton DL, (1987) Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site. Arch Surg 122: 1380-1383.
40. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, et al. (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634.
41. Markowitz JS, Cosimi LA, Carey RW, Kang S, Padyk C, et al. (1991) Prognosis after initial recurrence of cutaneous melanoma. Arch Surg 126: 703-707.
42. Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM, (1998) Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 67: 228-233.
43. Brand CU, Ellwanger U, Stroebel W, Meier F, Schlagenhauff B, et al. (1997) Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 79: 2345-2353.